Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isoglycyrrhizin, pharmaceutical composition and application of isoglycyrrhizin for preparing medicine for treating diabetic cardiomyopathy

A technology of diabetic cardiomyopathy and isoliquiritigenin, applied in the field of drugs for organ damage, can solve the problems of immature development and application, and achieve the effects of delaying the progression of the disease, lowering the cost, and reducing the cost of diagnosis and treatment

Inactive Publication Date: 2019-03-01
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Isoliquiritigenin is currently commonly used in cosmetics and food additives, and it is still immature for development and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoglycyrrhizin, pharmaceutical composition and application of isoglycyrrhizin for preparing medicine for treating diabetic cardiomyopathy
  • Isoglycyrrhizin, pharmaceutical composition and application of isoglycyrrhizin for preparing medicine for treating diabetic cardiomyopathy
  • Isoglycyrrhizin, pharmaceutical composition and application of isoglycyrrhizin for preparing medicine for treating diabetic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0072] Effects of ISL on organ complications in STZ-induced type 1 diabetic mice

[0073] Male C57BL / 6 mice were obtained from the Animal Experiment Center of Wenzhou Medical University. Mice were housed in a thermostated 12-12h diurnal animal room with standard rodent chow and water. Animals underwent more than one week of environmental adaptation before the start of the experiment.

[0074] 8-10 weeks old male C57BL / 6 mice were randomly divided into 4 groups: normal control group, diabetic group (STZ), diabetic group combined with ISL treatment group (two doses of 10 and 20 mg / kg / d, expressed as STZ+ ISL10, STZ+ISL20, intragastric administration); 8 rats in each group.

[0075] Wherein, the preparation method of the diabetic mouse model is as follows:

[0076] Low-dose 50mg / kg / d streptozotocin (STZ, sigma) intraperitoneal injection, continuous injection for 5 days to build a type 1 diabetes model, after 72 hours, blood glucose meter to measure fasting blood glucose (fasti...

experiment example 2

[0085] Effects of ISL on cardiac complications in STZ-induced type 1 diabetic mice

[0086]After each group of mice in Experimental Example 1 was sacrificed, the heart tissue was taken, embedded in paraffin, and detected by Masson (Masson) and Sirius red (Sirus red) staining for cardiac morphological changes. Nick-End Labeling) technology was used to detect the changes of cardiomyocyte apoptosis. The normal control group is represented by Veh, the diabetes group is represented by STZ-DM1, and the medication group is represented by STZ-DM1+ISL. The results are as follows figure 1 and figure 2 shown, where:

[0087] figure 1 Middle D is the rendering of mouse cardiac connective tissue stained with Sirius red, figure 2 where E is figure 1 The statistical graph of D in D, by figure 1 D and figure 2 E shows that ISL can significantly reduce the ratio of cardiac connective tissue in STZ-induced type 1 diabetic mice.

[0088] figure 1 Middle F is the rendering of the mous...

experiment example 3

[0093] Effects of ISL on cardiac inflammation and oxidative stress

[0094] After each group of mice in Experimental Example 1 was sacrificed, the heart tissue was taken, and the inflammatory factor (TNF-α) and macrophage marker (F4 / 80) of the heart tissue were detected by immunohistochemistry, and the DHE fluorescent dye ( Dihydroethidium superoxide anion fluorescence) to detect reactive oxygen species (ROS) production in the heart, and oxidative stress-related factors (3-NT) by immunohistochemistry.

[0095] The normal control group is represented by Veh, the diabetes group is represented by STZ-DM1, and the medication group is represented by STZ-DM1+ISL. For the experimental results, see image 3 and Figure 4 . in,

[0096] image 3 Middle A is the effect diagram of detecting macrophage markers (F4 / 80) in cardiac tissue by immunohistochemistry, Figure 4 B is image 3 The statistical graph of A. Depend on image 3 A and Figure 4 B shows that ISL can significantly...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides a pharmaceutical composition for improving inflammation and an oxidative stress reaction, and further provides application of isoglycyrrhizin for preparing medicine for treatingdiabetic cardiomyopathy. The composition comprises the isoglycyrrhizin. The isoglycyrrhizin acts individually or as an active ingredient in the pharmaceutical composition to reduce the pathological damage of heart tissue by relieving and treating myocardial inflammation and the oxidative stress reaction, and the diabetic cardiomyopathy can be treated. The isoglycyrrhizin is safe in use, has no toxic and side effects and high operability, facilitates delaying the disease progression, and improves the quality of life of patients.

Description

technical field [0001] The invention relates to a medicine for treating organ damage caused by diabetes or high sugar, in particular to the use of isoliquiritigenin or a pharmaceutical composition containing isoliquiritigenin in the preparation of medicine for treating diabetes or high sugar-induced myocardial injury. Background technique [0002] With the development of society, the prevalence of Diabetes Mellitus (DM) has increased significantly, and it has become an epidemic disease that affects human health. Diabetic cardiomyopathy (DCM) is one of the main cardiac complications of diabetic patients, which ultimately leads to high mortality and disability in diabetes. The disease causes extensive focal necrosis of the myocardium on the basis of metabolic disorders and microvascular lesions, which affects the systolic and diastolic functions of the heart, and eventually develops into congestive heart failure, arrhythmia, and cardiogenic shock, with a poor prognosis. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/12A61P3/10A61P9/04A61P9/00
CPCA61K31/12A61P3/10A61P9/00A61P9/04
Inventor 陈雄肖方毅陈肖俊尤圣办胡珦虞伟慧孙洪伟施玉娟谷雪梅梁广
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com